Viatris (VTRS) Capital Expenditures (2020 - 2026)
Viatris (VTRS) posted quarterly Capital Expenditures of $39.9 million for Q1 2026, down 6.34% year-over-year from $42.6 million in Q1 2025, and down 79.69% quarter-over-quarter from $196.5 million in Q4 2025.
Viatris (VTRS) Capital Expenditures (2020 - 2026) Analysis & Trends
Viatris' Capital Expenditures history runs 7 years deep, the most recent figure standing at $39.9 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 6.34% year-over-year to $39.9 million; the TTM figure through Mar 2026 stood at $376.1 million (up 17.97% YoY), while the FY2025 annual figure was $378.8 million, up 16.2% from the prior year.
- Capital Expenditures for Q1 2026 stood at $39.9 million, down from $196.5 million in the prior quarter.
- The five-year high for Capital Expenditures was $196.5 million in Q4 2025, with the low at $39.9 million in Q1 2026.
- The 5-year median for Capital Expenditures is $77.0 million (2024), against an average of $89.9 million.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures fell 25.89% in 2023, then jumped 39.96% in 2025.
- Viatris' Capital Expenditures stood at $153.7 million in 2022, then gained by 7.68% to $165.5 million in 2023, then declined by 15.17% to $140.4 million in 2024, then jumped by 39.96% to $196.5 million in 2025, then sank by 79.69% to $39.9 million in 2026.
- Business Quant data shows VTRS's Capital Expenditures at $39.9 million in Q1 2026, $196.5 million in Q4 2025, and $86.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.80 Mn |
| Jun 30, 2026 | 52.80 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Dec 31, 2025 | 196.50 Mn |
| Dec 31, 2025 | 196.50 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Jun 30, 2025 | 52.90 Mn |
| Jun 30, 2025 | 52.90 Mn |
| Mar 31, 2025 | 42.60 Mn |
| Mar 31, 2025 | 42.60 Mn |
| Dec 31, 2024 | 140.40 Mn |
| Dec 31, 2024 | 140.40 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Jun 30, 2024 | 58.80 Mn |
| Jun 30, 2024 | 58.80 Mn |
| Mar 31, 2024 | 49.80 Mn |
| Mar 31, 2024 | 49.80 Mn |